Article ID Journal Published Year Pages File Type
5502654 Journal of the Neurological Sciences 2017 6 Pages PDF
Abstract
In patients with anti-NMDAR encephalitis who did not respond to first-line immunotherapy, early application of lower dosages of rituximab could efficiently reduce CD19+ B-cell counts of peripheral blood and improve the prognosis of anti-NMDAR encephalitis.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Ageing
Preview
Lower dosages of rituximab used successfully in the treatment of anti-NMDA receptor encephalitis without tumour
Authors
, , , , ,